Morgan Stanley assumed coverage on shares of Grifols (NASDAQ:GRFS - Free Report) in a research report released on Wednesday morning. The firm issued an overweight rating on the biotechnology company's stock.
Separately, Berenberg Bank upgraded shares of Grifols to a "strong-buy" rating in a research note on Tuesday, October 29th.
Check Out Our Latest Analysis on GRFS
Grifols Stock Down 2.0 %
NASDAQ GRFS traded down $0.15 during mid-day trading on Wednesday, hitting $7.32. The stock had a trading volume of 378,114 shares, compared to its average volume of 804,338. Grifols has a twelve month low of $5.30 and a twelve month high of $9.96. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The firm's 50 day moving average is $7.38 and its 200 day moving average is $8.09.
Institutional Trading of Grifols
Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its position in shares of Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 1,135 shares during the period. R Squared Ltd bought a new position in Grifols during the fourth quarter worth $28,000. Signaturefd LLC lifted its position in Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 2,153 shares during the period. Blue Trust Inc. raised its stake in Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 4,970 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Grifols by 354.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 6,335 shares during the last quarter.
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Stories
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
